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We present a dialysis technique to prepare the 10-hydroxycamptothecin (HCPT)-loaded nanoparticles (NPs) using
methoxypolyethylene glycol-poly(D,L-lactide) (PEG-b-PLA) and PLA, respectively. Both HCPT-loaded PEG-b-PLA NPs
and HCPT-loaded PLA NPs were characterized by differential scanning calorimetry (DSC), dynamic light scattering
(DLS), transmission electron microscopy (TEM), scanning electron microscopy (SEM) and confocal laser scanning
microscopy (CLSM). The results showed that the HCPT-loaded PEG-b-PLA NPs and HCPT-loaded PLA NPs presented
a hydrodynamic particle size of 120.1 and 226.8 nm, with a polydispersity index of 0.057 and 0.207, a zeta potential
of −31.2 and −45.7 mV, drug encapsulation efficiency of 44.52% and 44.94%, and drug-loaded content of 7.42%
and 7.49%, respectively. The HCPT-loaded PEG-b-PLA NPs presented faster drug release rate compared to the
HCPT-loaded PLA NPs. The HCPT-loaded PEG-b-PLA NPs presented higher cytotoxicity than the HCPT-loaded PLA
NPs. These results suggested that the HCPT-loaded PEG-b-PLA NPs presented better characteristics for drug delivery
compared to HCPT-loaded PLA NPs.
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Nowadays, cancer is one of the most common causes of
death all over the world. Chemotherapy is still a com-
monly used strategy for cancer treatment [1,2], but their
efficacy is largely limited by low stability, short circulat-
ing half-life, and the toxicity associated with the antican-
cer drugs to normal tissues [3-6]. The nanoparticles
(NPs) have been proposed to overcome these inconve-
niencies, for NPs can encapsulate a series of poorly
water-soluble anticancer drugs and reduce their toxicity
by the way of releasing them in a sustained manner at
their target site [1,7-10]. In addition, the self-assembly
technique is a simple and low-cost method for produ-
cing NPs in a controllable way [11,12]. Hence, the self-
assembled NPs have attracted considerable interest for
their potential use in anticancer drug delivery system.* Correspondence: yeshefang@xmu.edu.cn; houzhenqing@xmu.edu.cn
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in any medium, provided the original work is pAlthough the NPs enhanced the stability and de-
creased the toxicity of drugs, they only solved part of the
problems, since the particles could be still rapidly
cleared by the reticuloendothelial system (RES) uptake
[11,13]. It was pointed that hydrophobic NPs were more
prone to RES uptake as compared to the negatively
charged NPs [14]. So the NPs with surface modification
have been devised to further improve the suboptimal
pharmacokinetic properties [15-17]. Among all the strat-
egies, PEGylation was proved to be the most effective,
because of its unique physicochemical characteristics,
such as good dispersibility and solubility [18-20]. With
PEG chains on their surface, the NPs can entangle water
molecules in the aqueous phase, which will render their
surface hydrophilic and hinder protein binding and RES
uptake [3]. It can still enhance their solubility and di-
minish their aggregation and immunogenicity [21]. More
importantly, polyethylene glycol has been approved by
FDA for human use. All these properties contribute to
wide-spread use of PEG in many therapeutics [3,16,21].
10-Hydroxycamptothecin (HCPT) is a promising
broad-spectrum antitumor agent which has shown toOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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oma, hepatoma, leukemia, and tumor of the head and
neck in clinical practice [22]. In spite of its remarkable
success in early clinical trials, the application of HCPT is
still largely limited because of its poor solubility and
stability, which led to low therapeutic efficiency and a
number of side effects owing to the conversion of HCPT
from active lactone form to the inactive carboxylate
form under physiologic conditions [5,23]. For these rea-
sons, we chose HCPT as the model chemotherapeutic
agent, expecting to further improve the suboptimal
pharmacokinetic properties and promote its clinical
application.
Moreover, testing tools are also important for future
clinic use, and fluorescence imaging technique is an effect-
ive research tool to investigate many in vivo processes in
the life sciences, such as the locations and sizes of tumors
and the distribution of chemotherapy agents [24,25]. The
intrinsically fluorescence properties of HCPT in the drug
delivery system will provide a good signal readout for the
detection, which will meet the requirements of cancer
diagnosis and therapy simultaneously.
In this paper, we presented a dialysis technique to dir-
ect the self-assembly of the HCPT-loaded PEG-b-PLA
NPs. The hydrophobic polymeric core of the platform
readily encapsulated the water-insoluble drug for sys-
temic drug delivery. The physicochemical properties of
the HCPT-loaded PEG-b-PLA NPs were characterized
by differential scanning calorimetry (DSC), dynamic light
scattering (DLS), scanning electron microscope (SEM),
transmission electron microscopy (TEM), and confocal
laser scanning microscopy (CLSM). In vitro drug release
profiles and cytotoxicity tests were also conducted. The
HCPT-loaded PLA NPs were also prepared and charac-
terized in the same way and used for comparison.
Methods
Materials
All chemicals were analytical grade and used as received
without further purification. The ultrapure water (18 M
Ω∙cm−1) was used throughout the work. The 10-HCPT
(purity >99%) was purchased from Lishizhen Pharma-
ceutical Co, Ltd (Wuhan, Hubei, China). PLA (50 kDa)
and PEG-b-PLA (10%) were provided by Daigang BIO
Engineer Co., Ltd. (Shandong, China). A dialysis bag
(Mw cutoff = 8,000 to 14,000 Da) was ordered from
Greenbird Inc. (Shanghai, China).
Preparation of the HCPT-loaded PEG-b-PLA NPs and
HCPT-loaded PLA NPs
The HCPT-loaded PEG-b-PLA NPs were prepared by a
facile dialysis method. In brief, 100 mg of PEG-b-PLA
was dissolved in 10 mL of acetone (solution A), and
10 mg of HCPT was dissolved in 0.5 mL of 0.01 MNaOH solution (solution B). Then solution B was
dropped into solution A, and the mixture was used as
the organic phase. Subsequently, the resulting organic
phase was then introduced into a dialysis bag and dia-
lyzed against 1,000 mL of water as the aqueous phase
for 8 h. The as-prepared HCPT-loaded PEG-b-PLA NPs
were lyophilized for 24 h using a freeze drier (Labconco
Plus 12, Labconco, Kansas City, MO, USA) and stored
at 4°C for use. The HCPT-loaded PLA NPs were pre-
pared in a similar way using 100 mg of PLA. The drug-
loaded content and drug encapsulation efficiency of both
HCPT-loaded PEG-b-PLA NPs and HCPT-loaded PLA
NPs were determined with ultraviolet spectrophotometry
at 383 nm. The drug-loaded content and drug encapsula-
tion efficiency were presented by the following equations:
Drug‐loaded content %ð Þ ¼ Weight of HCPT in NPsð Þ
 Weight of NPsð Þ  100%
Drug encapsulation efficiency %ð Þ ¼ Weight of HCPT in NPsð Þ
 Weight of feeding drugð Þ
 100%
DSC analysis
The DSC analysis was performed on the solid samples
using Netzsch model DSC-204 (Netzsch, Selb, Germany)
with heating cycles of 0°C to 200°C. Samples (4 to 5 mg)
were placed in a sealed aluminum pan and heated
continuously at the rate of 10°C min−1 under a constant
flow (40 mL min−1) of N2.
Particle size, polydispersity index, surface charge,
morphology, and HCPT distribution
The average particle size, zeta potential, and polydisper-
sity index (PDI) were determined DLS using Malvern
Zetasizer Nano-ZS (Malvern Instruments, Worcestershire,
UK). The morphology of the HCPT-loaded PEG-b-PLA
NPs was examined by SEM (LEO 1530; ZWL, Pegnitz,
Germany) and TEM (JEM-2100; JEOL Ltd., Tokyo, Japan)
at 20 and 200 kV, respectively. One drop of the suspension
was placed on a silicon wafer or a carbon-coated copper
grid and dried in the air before observation. The distribu-
tion of HCPT within the HCPT-loaded PEG-b-PLA NPs
was analyzed by CLSM (Olympus FV 1000; Olympus,
Tokyo, Japan). The HCPT-loaded PLA NPs were used for
comparison.
In vitro drug release behavior
The in vitro drug release studies of the HCPT-loaded
PEG-b-PLA NPs were performed using the dialysis tech-
nique. The particles were dispersed in PBS (10 mL) and
placed into a pre-swelled dialysis bag (MWCO 3,500 Da).
The dialysis bag was then immersed in 0.1 M PBS at
pH 7.4 and oscillated continuously in a shaker incubator
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cence spectrophotometry (HORIBA Fluoromax-4; HOR-
IBA Ltd, Minami-ku, Kyoto, Japan). The HCPT-loaded
PLA NPs were used for comparison.In vitro cell viability assays
Human hepatocellular carcinoma cells (BEL-7402) were
cultured in standard cell media recommended by the
American Type Culture Collection. The cells seeded in
96-well plates were incubated with a series of increasing
concentrations of the HCPT-loaded PEG-b-PLA NPs for
48 h. Subsequently, the relative cell viability was assessed
by the standard MTT assay. Cells treated with free
HCPT and cells treated with the HCPT-loaded PLA NPs
were compared.Figure 1 Schematic representations of HCPT-loaded PLA NPs and HCPResults and discussion
Preparation of the HCPT-loaded PEG-b-PLA NPs
HCPT has a rather poor solubility for most organic
solvents, so NaOH solution is used to dissolve HCPT.
Acetone is water-miscible and a good solvent for PEG-b-
PLA, so it is chosen as the organic phase. Firstly, PEG-
b-PLA was dissolved in acetone (solution A) and HCPT
was dissolved in NaOH solution (solution B). When so-
lution B was dropped into solution A, PEG-b-PLA and
HCPT were codissolved in this mixed solution, which
was used as the organic phase and then extensively dia-
lyzed against the aqueous phase. In the dialysis process,
acetone was gradually removed and slowly replaced with
water. To attain the minimal energy state, the hydropho-
bic PLA assembled together and formed a core while the
hydrophilic PEG extended to the aqueous environmentT-loaded PEG-b-PLA NPs.
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hydrophobic interaction, HCPT spontaneously trans-
ferred into the hydrophobic cores of the NPs. Although
both of PEG-PLA and PLA particles were prepared by
the same dialysis method, their formation mechanisms
are different: the amphiphilic PEG-PLA formed micelles-
like particles with core-shell structure; however, the ho-
mopolymer of PLA formed homogeneous solid particles.
The determined drug entrapment efficiency and drug-
loaded content of HCPT-loaded PEG-b-PLA NPs deter-
mined by ultraviolet spectrophotometry were 44.52% ±
0.42% and 7.42% ± 0.07%, respectively, and those of
HCPT-loaded PLA NPs were 44.94% ± 0.54% and 7.49% ±
0.09%, respectively.DSC analysis
The state of the incorporated drug in the HPLC-PEG-b-
PLA NPs was proved using DSC (Figure 2). Under the
experimental conditions, the DSC thermogram of the
free HCPT had two endothermic peaks at 68.286 and
107.456°C, whereas that of the blank PEG-b-PLA parti-
cles showed a sharp endothermic peak at 53.253°C. In
the curve of the HCPT-loaded PEG-b-PLA NPs, the
peaks of HCPT and the peak of PEG-b-PLA were still
existed, evidencing the presence of the crystalline drug
in the HCPT-loaded PEG-b-PLA NPs. And the curves of
PLA and HCPT-loaded PLA NPs also indicated the
crystalline state of the incorporated drug in the HCPT-
loaded PLA NPs.Figure 2 The DSC patterns. (a) Bulk HCPT. (b) PLA. (c) HCPT-loaded PLA NParticle size, PDI, surface charge, and morphology
Figure 3 showed that the particle size of the HCPT-
loaded PEG-b-PLA NPs was 120.1 ± 4.9 nm, much smaller
than that of the HCPT-loaded PLA NPs (226.8 ± 10.4 nm),
indicating that the HCPT-loaded PEG-b-PLA NPs will be
taken up easier by cancer cells, for smaller particle
size favors EPR targeting (enhanced permeability and
retention effect). The reason may be that the hydrophil-
icity of the polymer becomes stronger with PEGylation,
which can attain lower energy state than that without
PEGylation and form smaller particles. Moreover, due to
its lower PDI (0.057), the HCPT-loaded PEG-b-PLA NPs
would have a better dispersibility and stability than the
HCPT-loaded PLA NPs. Figure 3 also showed that the
HCPT-loaded PEG-b-PLA NPs and HCPT-loaded PLA
NPs presented a zeta potential of −31.2 and −45.7 mV,
for the oxygen atom of the PEG chains could combine
with a few hydrogen ions, which was positively charged,
and made the zeta potential lower. However, the zeta
potential of the two NPs was high enough to support
that these NPs could not aggregate much in aqueous
state in general and in physiologically relevant media in
particular.
The SEM images revealed that the HCPT-loaded PEG-
b-PLA NPs were regularly spherical in shape and had a
relatively smooth surface with a little more than 100 nm
in particle size, which was in accordance with the result
of DLS. While the HCPT-loaded PLA NPs showed uni-
form color in TEM images, the HCPT-loaded PEG-b-
PLA NPs contained a core particle with a lighter outerPs. (d) PEG-b-PLA. (e) HCPT-loaded PEG-b-PLA NPs.
Figure 3 Particle size and zeta potential. Particle size and zeta potential of HCPT-loaded PEG-b-PLA NPs and HCPT-loaded PLA NPs.
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bic core, made up of PLA and HCPT, and the hydro-
philic shell, made up of PEG chain, respectively.
The distribution of HCPT was showed in Figure 5.
The green fluorescence imaging (excitation at 382 nm)
was performed to visualize HCPT in the NPs. In the
HCPT-loaded PLA NPs, green fluorescence imaging
overlapped nicely with the image of the particles, whichFigure 4 Electron microscopy images. SEM images of HCPT-loaded PLA
HCPT-loaded PLA NPs (C) and HCPT-loaded PEG-b-PLA NPs (D).indicated that HCPT was uniformly distributed within
the particles. However, in the HCPT-loaded PEG-b-PLA
NPs, the green fluorescence only appeared in the core of
the NPs, demonstrating that HCPT only existed in the
hydrophobic core of the particles. The results of the
TEM and CLSM images both confirm the core-shell ar-
chitectures of the HCPT-loaded PEG-b-PLA NPs: HCPT
and PLA formed the core, and PEG formed the shell.NPs (A) and HCPT-loaded PEG-b-PLA NPs (B) and TEM images of
Figure 5 CLSM images of HCPT-loaded PEG-b-PLA NPs (A) and HCPT-loaded PLA NPs (B).
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NPs was enhanced in the dispersion, and the particle
size was decreased.
In vitro drug release behavior
The release behavior of the NPs is an important aspect
because this information is directly related to the design
of the nanodrug delivery system. An in vitro release
study of the HCPT-loaded PEG-b-PLA NPs (7.0% con-
tent) was performed and that of HCPT-loaded PLA NPsFigure 6 In vitro release profiles of HCPT-loaded PEG-b-PLA NPs and(6.9% content) was used as comparison. As shown in
Figure 6, both two NPs exhibited a slow, prolonged
release profile over a period of 750 h. While the release
rate was a little faster, the total HCPT released from the
HCPT-loaded PEG-b-PLA NPs was 63.0%, much higher
than that of the HCPT-loaded PLA NPs. The profiles
may be explained by two factors. Firstly, the particle size
of the HCPT-loaded PEG-b-PLA NPs was much smaller
than that of the HCPT-loaded PLA NPs, reducing the
total releasing time of the drug from the NPs. Second,HCPT-loaded PLA NPs in PBS (1/15 M, pH 7.4).
Figure 7 The in vitro cytotoxicity assay against human liver BEL-7402 cells (48 h); p < 0.05.
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loaded PEG-b-PLA NPs was used as a buffer role,
which could reduce the hydrophobic interaction be-
tween the drug and polymer matrix and facilitate the
release of the drug from the NPs core. Both of the
factors could promote the release of HCPT from the
HCPT-loaded PEG-b-PLA NPs.In vitro cell viability assays
The cytotoxicity of the HCPT-loaded PEG-b-PLA NPs
and HCPT-loaded PLA NPs was investigated and com-
pared with bulk HCPT using BEL-7402 cells. As shown
in Figure 7, at equivalent concentrations of HCPT, the
HCPT-loaded PEG-b-PLA NPs showed higher cytotox-
icity than the HCPT-loaded PLA NPs at equivalent
concentrations of HCPT. The possible reasons are as
follows. Firstly, the release rate of the HCPT-loaded
PEG-b-PLA NPs was faster, and the total HCPT re-
leased was much more than HCPT-loaded PLA NPs
(see Figure 6). Secondly, the particle size of the HCPT-
loaded PEG-b-PLA NPs was much smaller, leading to the
easier cellular uptake and more drug accumulation inside
the cell and thus to the enhanced cytotoxicity. HCPT
showed the highest inhibition rate, mainly ascribing to
the fact that HCPT would directly act on the target site
inside the cells without drug release with increasing
intracellular drug concentration to a high level within
24 h.Conclusions
In this study, we developed a simple but successful
method to obtain both HCPT-loaded PEG-b-PLA NPs
and HCPT-loaded PLA NPs with fine characteristics for
drug delivery. Although both exhibiting a slow, pro-
longed release profile, the HCPT-loaded PEG-b-PLA
NPs presented a smaller particle size, faster drug release,
and higher cell cytotoxicity compared to the HCPT-
loaded PLA NPs. The animal experiments are going on
now. The results obtained in this study indicate that
these NPs might become a promising drug delivery
system for HCPT.
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